-
After a heart attack, beta-blockers are often a lifelong medicine. Maybe they shouldn’t be for stable low-risk post-MI patients
Medical Mythbusting Commentary for March 31, 2026 Source:After a heart attack, beta-blockers are often a lifelong medicine. Maybe they shouldn’t be
-
The reason Vitamin K1 is given to newborns and why it has been a standard of care for over 65 years.
Medical Mythbusting Commentary for March 26, 2026 Source:It’s not just vaccines: Parents are refusing other routine preventive care for newborns
-
It stands to reason that most medications designed to manage progressive chronic disease once discontinued will see a relapse or progression of said disease process.
Medical Mythbusting Commentary for March 25, 2026 Source:Stopping GLP-1 drugs like Ozempic erodes heart health benefits quickly, new study finds Reference:GLP-1RA discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: A target emulation trial.
-
Limited power study with negligible clinical significant reports low doses of lithium may slow verbal memory decline from Alzheimer’s
Medical Mythbusting Commentary for March 10, 2026 Source:Low doses of lithium may slow verbal memory decline from Alzheimer’s Reference:Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial
-
What is the evidence that GLP-1 medications such as Ozempic and Mounjaro might help treat addiction?
Medical Mythbusting Commentary for March 9, 2026 Source:What to know about how GLP-1 medications such as Ozempic and Mounjaro might fight addiction Reference:Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study
-
The time of day when a dose of immunochemotherapy is given in non-small cell lung cancer may have an impact on treatment efficacy.
Medical Mythbusting Commentary for February 17, 2026 Source:How well a cancer treatment works may depend on the time of day you get it Reference:Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial
-
Oral version of injectable cholesterol-lowering medication completes phase 3 trial with noted reductions in LDL-cholesterol as well as lipoproteins.
Medical Mythbusting Commentary for February 9, 2026 Source:Experimental cholesterol-lowering pill may offer new option for millions Reference:A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
-
What cannabis really does for chronic pain
Medical Mythbusting Commentary for January 30, 2026 Source:What cannabis really does for chronic pain Reference:Cannabis-Based Products for Chronic Pain
-
Intestinal bacterial replacement pills show safety and reduced the side effects from chemotherapy agents used to treat advanced kidney cancer in Phase 1 study
Medical Mythbusting Commentary for January 29, 2026 Source:‘Poop pills’ developed in London show promise for cancer patients in early trial